Insights

Strategic Partnerships Depixus has active collaboration with Daiichi Sankyo to apply MAGNA technology in RNA-targeted drug discovery, presenting an immediate sales avenue for workflow integration, service support, and expanded access programs with large pharma.

New Instrument Launch The MAGNA One launch signals a scalable hardware platform for real-time biomolecular interaction analysis, creating opportunities to upsell instrument coverage, maintenance contracts, training, and co-selling with distributors or systems integrators.

Awarded For Innovation Multiple SLAS Ignite recognitions position Depixus as a fast-emerging innovator, enhancing credibility for outreach to life sciences customers seeking cutting-edge interactomics solutions and potential pilot programs.

Commercialization Momentum Appointment of a Chief Commercial Officer in early 2024 indicates a dedicated go-to-market effort, suggesting readiness for targeted outreach to biotechs and pharmaceutical R&D labs needing rapid adoption of MAGNA technology.

Funding & Growth Despite a small revenue base, substantial funding combined with a technology access program implies favorable financing options, potential for sponsored research, and pilot deployments to de-risk customer adoption.

Similar companies to Depixus

Depixus Tech Stack

Depixus uses 8 technology products and services including SOLIDWORKS, WordPress, Salesforce, and more. Explore Depixus's tech stack below.

Media & News

Depixus's Email Address Formats

Depixus uses at least 3 email formats:
Depixus Email FormatsExamplePercentage
First.Last@depixus.comJohn.Doe@depixus.com
96%
First.Middle@depixus.comJohn.Michael@depixus.com
2%
First@depixus.comJohn@depixus.com
2%

Frequently Asked Questions

What is Depixus's official website and social media links?

Minus sign iconPlus sign icon
Depixus's official website is depixus.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Depixus generate?

Minus sign iconPlus sign icon
As of September 2026, Depixus's annual revenue is estimated to be <$1M.

What is Depixus's SIC code and NAICS code?

Minus sign iconPlus sign icon
Depixus's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Depixus have currently?

Minus sign iconPlus sign icon
As of September 2026, Depixus has approximately 35 employees across 2 continents, including Europe and South America. Key team members include Chief Business Officer: S. A., Vice President Of Engineering: T. V. and Head Of Asia-Pacific Strategy: Y. G. Explore Depixus's employee directory with LeadIQ.

What industry does Depixus belong to?

Minus sign iconPlus sign icon
Depixus operates in the Biotechnology Research industry.

What technology does Depixus use?

Minus sign iconPlus sign icon
Depixus's tech stack includes SOLIDWORKS, WordPress, Salesforce, NetSuite, Microsoft 365, WP Engine, Adobe Creative Suite and LabVIEW.

What is Depixus's email format?

Minus sign iconPlus sign icon
Depixus's email format typically follows the pattern of First.Last@depixus.com. Find more Depixus email formats with LeadIQ.

How much funding has Depixus raised to date?

Minus sign iconPlus sign icon
As of September 2026, Depixus has raised $38M in funding. The last funding round occurred on Jan 15, 2022 for $35M.
Depixus logo

Depixus

Biotechnology ResearchÎle-de-France, France11-50 Employees

Depixus SAS is a life sciences technology company based in Paris, France, that develops and commercializes a platform centered on analyzing interactions between biomolecules in real time. The technology enables researchers to study individual molecular interactions at scale, supporting efforts to understand disease mechanisms and accelerate the development of therapies. The company operates within the biotechnology research sector and targets researchers and organizations engaged in drug discovery and translational science, offering a means to gain deeper insights into molecular behavior that can inform therapeutic strategies. Recent actions include the launch of MAGNA One, described as a laboratory instrument capable of analyzing biomolecular interactions at scale, reflecting the company's focus on expanding access to its interactomics technology. Depixus has established collaborations with industry partners and has appointed leadership to advance commercialization of its MAGNA technology, positioning itself as a specialized supplier within the interactomics space in the Île-de-France region.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $38M

    Depixus has raised a total of $38M of funding over 4 rounds. Their latest funding round was raised on Jan 15, 2022 in the amount of $35M as a Series A.

  • <$1M

    Depixus's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.